Search KLH Site
Find Articles by Tags
Addiction (18) Adjuvant - Alum (1) Adjuvant - GPI-0100 (1) Adjuvant - IL-4 (9) Adjuvant GM-CSF (16) Adjuvant KLH (4) Adjuvant Oil / Surfactant (4) Adjuvant QS-21 (25) Age & Physical Activity (3) Allergen-specific immunotherapy (1) Allergy – Pollen (2) Alzheimer's Disease (3) Antibody Response (35) Antibody Response IgA (14) Antibody Response IgE (6) Antibody Response IgG (106) Antibody Response IgM (71) Antibody Response IgY (1) APEC (1) Assay - Bioassay (2) Assay - Carbohydrate Microarray (1) Assay - ELISA (55) Assay - ELISPOT (7) Assay - Immunoassay (8) Assay - InVitro (18) Assay - InVivo (1) Atopic Dermatitis (1) Autoimmune Disease (1) B-epitope (1) Bone Marrow Transplant (6) Cancer (6) Cancer - Bladder (16) Cancer - Brain & CNS (8) Cancer - Breast (15) Cancer - Cervical (1) Cancer - Colorectal (10) Cancer - Esophageal (1) Cancer - Female Reproductive (7) Cancer - Leukemia (2) Cancer - Lung (4) Cancer - Lymphoma (25) Cancer - Melanoma (37) Cancer - Mesothelioma (1) Cancer - Myeloma (15) Cancer - Other (2) Cancer - Ovarian (3) Cancer - Pancreas (1) Cancer - Pediatric (3) Cancer - Peritoneal (2) Cancer - Prostate (9) Cancer - Renal (13) Cancer - Sarcoma (2) Clostridium difficile (5) Crohn's Disease (2) Cross-Reactive Antigens (6) Delayed-type hypersensitivity response (1) Dendritic Cell (66) Developmental (10) Diabetes (2) Disease Resistence (1) DNP-Ficoll (2) DTH (67) Environmental (15) Escherichia coli (1) Fingolimod (Gilenya) (1) Healthy Volunteers (18) HealthyAntibody Response - IgA (1) Hepatitis (2) HIV (11) HPV (3) Husbandry (3) Hypertension (1) id-KLH (29) IL 1 (4) IL 12 (2) IL 15 (1) IL 2 (10) IL 5 (1) IL 6 (1) IL 7 (1) Immune Disease - Autoimmune (13) Immune Disease - Primary (2) Immune Disease – Secondary (1) Immune Response - Cellular (187) Immune Response - Humoral (259) Immune Response Humoral (2) Immunotoxicity (37) Infection (1) Infectious Disease (5) Inflammatory Disease (1) Intradermal KLH (1) Kidney (1) KLH-BEC2 (1) KLH-BP16 (1) KLH-BPO (1) KLH-Conjugate (69) KLH-EGFR (2) KLH-FITC (1) KLH-Ganglioside (16) KLH-Globo H (7) KLH-GM2 (1) KLH-hD1 (1) KLH-HGP-30 (1) KLH-IL (1) KLH-Kinoid (8) KLH-Lewis Y (3) KLH-MUC (8) KLH-Oxycodone (2) KLH-sTn (9) KLH-TF (5) KLH-TN (3) Model - Canine (6) Model - Guinea Pig (10) Model - Livestock (10) Model - Mouse (73) Model - Other (32) Model - Primate (12) Model - Rat (51) Multiple Sclerosis (1) Nasal (3) Natrural Antibody (1) Neonatal (2) NK Cells (1) NSAID (1) Oral KLH (9) Oxycodone (3) Parasitic Disease (6) Pediatric (1) Plant-made (2) PLNA (1) Population Density (3) Psoriasis (1) Review Article (2) Rheumatoid Arthritis (11) Rituximab (Rituxan) (4) Russian thistle (1) Sal k 1 (1) Stress (8) Systemic Lupus Erythematosus (SLE) (7) TACA (2) TDAR (127) Therapeutics - KLH Alone (15) Transplant (6) Ultra Violet radiation (1) Uveitis (1) VEGF (3) Veterinary (1)
Terms and Privacy

KLH in Publications

Publications of scientific research involving KLH. Abstracts or full text articles are available by link to outside sites. If you know of a KLH-related publication that is not yet on KLH Site™, let us know.

(in order by date)

Entries in Adjuvant QS-21 (25)

Tuesday
Feb122013

Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer

Yen-Lin Huang, Jung-Tung Hung, Sarah K. C. Cheung, Hsin-Yu Lee, Kuo-Ching Chu, Shiou-Ting Li, Yu-Chen Lin, Chien-Tai Ren, Ting-Jen R. Cheng, Tsui-Ling Hsu, Alice L. Yu, Chung-Yi Wu, and Chi-Huey Wong

Proc Natl Acad Sci U S A. 2013 February 12; 110(7): 2517–2522.

Friday
Jun112010

Preclinical Evaluation of the Synthetic Adjuvant SQS-21 and its Constituent Isomeric Saponins

Govind Ragupathi, Payal Damani, Kai Deng, Michelle M. Adams, Jianfeng Hang, Constantine George, Philip O. Livingston, and David Y. Gin.

 Vaccine. 2010 June 11; 28(26): 4260–4267

Wednesday
Feb172010

Design and Synthesis of Potent Quillaja Saponin Vaccine Adjuvants

Michelle M. Adams, Payal Damani, Nicholas R. Perl, Annie Won, Feng Hong, Philip O. Livingston, Govind Ragupathi, and David Y. Gin.

J Am Chem Soc 2010 Feb 17; 132(6):1939

Sunday
Jul152007

Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO.

Clin Cancer Res. 2007 Jul 15;13(14):4170-7

Tuesday
Jul102007

A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".

Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI.

Cancer Immunol Immunother. 2007 Dec;56(12):1921-30. Epub 2007 Jul 10.

Tuesday
May152007

Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.

Gilewski TA, Ragupathi G, Dickler M, Powell S, Bhuta S, Panageas K, Koganty RR, Chin-Eng J, Hudis C, Norton L, Houghton AN, Livingston PO.

Clin Cancer Res. 2007 May 15;13(10):2977-85.

Monday
May022005

A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.

Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, Wilton AS, Powell S, Spassova M, Reis C, Clausen H, Danishefsky S, Livingston P, Scher HI.

Vaccine. 2005 May 2;23(24):3114-22.

Tuesday
Feb222005

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI.

Cancer Immunol Immunother. 2005 Jul;54(7):694-702. Epub 2005 Feb 22.

Wednesday
Sep152004

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.

Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6094-100.

Thursday
Jul152004

Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.

Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO

Clin Cancer Res. 2004 Jul 15;10(14):4717-23.

Sunday
Feb012004

Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.  

Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO.

Clin Cancer Res. 2004 Feb 1;10(3):916-23.

Monday
Dec012003

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

Slovin SFRagupathi GMusselli COlkiewicz KVerbel DKuduk SDSchwarz JBSames DDanishefsky SLivingston POScher HI.

J Clin Oncol. 2003 Dec 1;21(23):4292-8.

Monday
Oct012001

Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience

Musselli C, Livingston PO, Ragupathi G.

J Cancer Res Clin Oncol. 2001 Oct;127 Suppl 2:R20-6

Tuesday
May012001

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U.

J Clin Oncol. 2001 May 1;19(9):2370-80.

Thursday
Mar012001

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.

Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, Mascari R, Morrissey DM, Chapman PB.

J Clin Oncol. 2001 Mar 1;19(5):1430-6.

Friday
Dec012000

Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.

Chapman PB, Morrisey D, Panageas KS, Williams L, Lewis JJ, Israel RJ, Hamilton WB, Livingston PO.

Clin Cancer Res. 2000 Dec;6(12):4658-62.

Saturday
Jul012000

Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial.

Sabbatini PJ, Kudryashov V, Ragupathi G, Danishefsky SJ, Livingston PO, Bornmann W, Spassova M, Zatorski A, Spriggs D, Aghajanian C, Soignet S, Peyton M, O'Flaherty C, Curtin J, Lloyd KO.

Int J Cancer. 2000 Jul 1;87(1):79-85.

Monday
May012000

Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21

Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO

Clin Cancer Res. 2000 May;6(5):1693-701

Wednesday
Mar012000

Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study

Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO

Clin Cancer Res. 2000 Mar;6(3):874-9.

Wednesday
Mar012000

Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.

Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO.

Clin Cancer Res. 2000 Mar;6(3):874-9.